The relationship between systemic sclerosis and anti-fibrillarin antibodies.

Abstract

Systemic sclerosis, also known as scleroderma, is a complex autoimmune
condition that impacts the body's connective tissues. It involves abnormal growth of
connective tissue, resulting in skin and organ fibrosis, as well as vascular issues. A
key aspect of systemic sclerosis is the presence of autoantibodies, like anti-nuclear
antibodies (ANAs), which target cell nucleus components. Various ANA subtypes
linked to systemic sclerosis include anti-centromere, anti-topoisomerase (anti-Scl70), anti-RNA polymerase III, and anti-U3-RNP/fibrillarin antibodies. These
antibodies target specific proteins involved in ribosomal RNA processing. Detecting
ANAs, including anti-U3-RNP/fibrillarin antibodies, can aid in diagnosing and
managing systemic sclerosis. ANA testing can also help healthcare professionals
monitor disease progression and assess risks of complications like pulmonary
hypertension and lung disease.